Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 8/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 8/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.82 |
| ▸ | CASP1 | P29466 | 6/20 | 0.82 |
| ▸ | CASP7 | P55210 | 6/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.82 |
| ▸ | TP53 | P04637 | 6/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 5/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | XDH | P47989 | 3/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650613 | 0.91 | ABCB1 (1.00) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL31675757 | 0.91 | ABCB1 (1.00) | ABCB1MEN1KMT2AMAPTKDM4E | |
| Geraldol SCHEMBL620712 | 0.90 | MEN1 (1.00) | ABCB1MEN1KMT2AMAPTKDM4E | |
| Geraldol SCHEMBL29394734 | 0.90 | MEN1 (1.00) | ABCB1MEN1KMT2AMAPTKDM4E | |
| Geraldol SCHEMBL31122383 | 0.90 | MEN1 (1.00) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL14259686 | 0.87 | TUBB4A (0.71) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL16237902 | 0.86 | KDM4E (0.83) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL3718645 | 0.86 | MAPT (0.66) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL29870196 | 0.86 | ABCB1 (0.81) | ABCB1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL14697045 | 0.85 | TUBB4A (0.65) | ABCB1MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | ONCO3R THERAPEUTICS BV (BE) | 2026-04-21 | — | — | US | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| WO-2025068090-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| EP-3335140-B1 | SYSTEMS, APPARATUS, AND METHODS FOR ANALYZING AND PREDICTING CELLULAR PATHWAYS | MASSACHUSETTS INST TECHNOLOGY (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-113924146-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| CN-118359612-A | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-07-28 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3976178-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos N.V. (BE) | 2022-04-06 | — | — | EP | disclosed |
| US-11285158-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2022-03-29 | — | — | US | disclosed |
| EP-2999467-B1 | USE OF A COMBINATION OF TWO COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF BONE DISORDERS | INST NAT DE LA RECH AGRONOMIQUE INRA (FR) | 2020-01-08 | — | — | EP | disclosed |
| US-8466195-B2 | Methods and compositions for treating complications of diabetes and vascular diseases using flavones | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2013-06-18 | — | — | US | disclosed |
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1993579-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION/TREATMENT OF BONE DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099432-A2 | PHARMACEUTICAL COMPOSITION CONTAINING BUTEA ISOFLAVONES FOR THE PREVENTION /TREATMENT OF BONE DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | ABCB1 1486/4885MEN1 1318/4885KMT2A 4028/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | ABCB1 1597/4885MEN1 1960/4885KMT2A 3048/4885 |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | ABCB1 1486/4885MEN1 1318/4885KMT2A 4028/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | ABCB1 2342/4885MEN1 4515/4885KMT2A 2339/4885 |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, IFNG, COL1A1 | ABCB1 1810/4885MEN1 1876/4885KMT2A 3238/4885 |
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | IL23R, IL2, IL36G | ABCB1 1310/4885MEN1 3300/4885KMT2A 4509/4885 |
| US-11285158-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | SIK2, SIK1, SIK3 | ABCB1 2342/4885MEN1 4515/4885KMT2A 2339/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | ABCB1 1118/4885MEN1 2969/4885KMT2A 2812/4885 |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | ABCB1 2342/4885MEN1 4515/4885KMT2A 2339/4885 |
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | SOST, BPGM, PTMS | ABCB1 1555/4885MEN1 197/4885KMT2A 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.